Adverum biotechnologies, inc. (ADVM)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-64,486

-61,220

-66,060

-69,916

-72,627

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-114,454

-113,747

-105,447

-105,230

-53,336

-47,453

-43,750

-37,922

-33,250

-25,404

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,573

1,608

1,497

1,717

1,750

1,865

2,139

2,039

2,096

2,079

1,996

1,799

1,603

1,422

1,210

1,014

812

585

393

271

162

0

0

0

Stock-based compensation expense

9,899

8,231

8,565

11,765

13,432

14,134

13,839

10,256

8,723

8,403

8,652

9,228

11,416

14,273

17,076

14,816

11,505

11,209

8,513

9,225

8,567

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Amortization of premium and discounts on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-780

0

0

0

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

759

0

0

0

Amortization of premium and accrued interest on marketable securities

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use asset

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-36

-44

-42

160

17

65

238

-104

-10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

-

-

-

-

-

-

-

-

-886

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

Receivable from collaborative partner

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

5,954

1,143

91

1,702

793

1,873

1,180

-789

491

-1,252

422

832

-71

1,306

-585

-30

531

463

586

594

624

0

0

0

Other asset

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Accounts payable

-650

-752

-1,385

843

-67

172

1,061

-2,323

333

-762

-1,091

1,639

-111

222

-200

-2,223

-312

150

414

1,587

-6

0

0

0

Accrued expenses and other current liabilities

1,909

1,753

-3,136

-2,255

215

1,048

3,100

365

487

-352

225

715

-190

290

-1,041

812

724

1,705

1,970

1,871

2,904

0

0

0

Restructuring liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-988

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

0

0

-

-964

860

2,045

3,360

1,982

-332

-1,257

-2,313

0

0

0

-

-

-

-

Deferred rent

-

-

-

-

-1,243

-206

113

103

97

88

81

74

65

58

50

-62

-207

-330

-390

-363

-298

0

0

0

Lease liability

7,586

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-49,170

-47,065

-54,435

-54,197

-53,964

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-38,030

-38,366

-39,150

-38,723

-39,749

-35,338

-31,267

-27,020

-12,043

-5,648

0

0

0

Purchases of marketable securities

-

-

0

70,806

-

-

83,135

101,570

209,787

0

0

0

-

-

-

-

88,427

0

0

0

-

-

-

-

Maturities of marketable securities

148,517

126,141

103,567

120,391

148,979

0

0

0

-

-

-

-

37,738

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

19,247

11,031

5,110

2,779

809

750

666

969

1,016

1,842

2,018

2,553

2,412

1,676

2,633

2,703

2,992

3,168

1,954

1,307

943

0

0

0

Net cash provided by (used in) provided by investing activities

-68,073

-40,836

-4,682

46,806

69,444

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-137,695

38,775

69,761

79,446

84,828

-41,569

-71,995

-81,423

-89,677

-943

0

0

0

Proceeds from offering of common stock, net of issuance costs

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

138,954

0

0

0

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from issuance of common stock pursuant to option exercises

3,442

2,619

2,590

542

688

742

597

488

367

442

756

688

763

640

406

429

188

0

0

0

-

-

-

-

Taxes paid related to net share settlement of restricted stock units

1,470

1,565

1,459

894

1,191

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of BPI loan

112

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from a financing arrangement

-

-

-

-

100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

28,191

1,399

1,475

-219

69,949

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents and restricted cash

-89,052

-86,502

-57,642

-7,610

85,429

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

481

556

78

124

147

138,860

138,630

256,570

303,417

165,442

0

0

0

Effect of foreign currency exchange rate on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-269

-143

-94

-82

7

-9

-21

-18

-17

-11

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-175,513

822

30,595

40,765

45,233

61,944

35,347

148,109

201,680

158,840

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental schedule of noncash investing information
Fixed assets in accounts payable and current liabilities

5,242

4,963

1,869

1,876

1,616

245

29

-145

115

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued in connection with license agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Fixed assets in accounts payable and current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Deferred stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

379

0

0

0

Fixed assets in accounts payable, accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-